Cipla Ltd.

Cipla, one of India’s leading generic pharmaceutical companies, is planning to raise up to Rs 4,000 crore via issue of securities in both domestic and global markets.  The company could be raising fund via issue of shares or American Depository Receipts (ADRs) or Global Depository Receipts (GDRs) or Foreign Currency Convertible Bonds (FCCBs) or other securities, whether denominated in rupee or foreign currency through a public issue or a private placement. The company is seeking approval of shareholders to the aforesaid enabling resolutions by means of postal ballot.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.